Anti-Aging & Longevity

Tesamorelin

Price range: $228.00 through $464.00

Per vial

$22.80

10 vials per pack

Suggested retail

$68.40

3× markup · per vial

Free shipping on orders over $2,000

$300 store credit on any independent COA · results don't matter

Milligrams Per Vial

Warehouse

Clear

Delivery guarantee Reshipped free if it doesn't arrive
≥99% purity Manufacturer-direct production
Independent COAs View COAs for this product →
Store credit guarantee Send any COA result, get store credit

Tesamorelin - Stabilized GHRH Analog Research Peptide

Tesamorelin is a synthetic GHRH analog originally developed by Theratechnologies and approved by the FDA in 2010 as Egrifta for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. It is structurally a GHRH (1-44) molecule with a trans-3-hexenoyl (N-terminal) modification that protects against DPP-4 cleavage and gives it a substantially longer functional half-life than unmodified Sermorelin. In the peptide-research toolkit, Tesamorelin is the most-studied GHRH analog with a published clinical outcome dataset on visceral fat and IGF-1 endpoints.

Why Tesamorelin’s Stabilization Matters

Native GHRH (and Sermorelin) are degraded by DPP-4 within minutes, producing a short pulse of GH release. Tesamorelin’s trans-3-hexenoyl group blocks DPP-4 cleavage, which means a larger fraction of the dose reaches the pituitary GHRH receptor and the GH pulse it triggers is longer and larger. That stabilization is what produced the visceral-fat endpoints in the published HIV-lipodystrophy trials - results that shorter-acting GHRH analogs (like Sermorelin) do not have in clinical-trial form.

Pathway	What it does in plain terms
Pituitary GHRH receptor	Triggers a sustained pulse of GH release
DPP-4 resistance	Trans-3-hexenoyl group blocks enzymatic cleavage - half-life is extended
IGF-1 downstream	GH converts to IGF-1 in the liver - elevated across Phase 3 trials
Visceral adipose tissue	Reduction documented in HIV-lipodystrophy Phase 3 program

Tesamorelin vs Sermorelin vs CJC-1295 No DAC

All three are GHRH analogs that hit the same receptor; they differ in how long they stay active and in how much published outcome data exists for each.

Peptide	Modification	Half-life
Sermorelin	None - native GHRH (1-29)	~10-15 minutes
CJC-1295 No DAC	4 DPP-4-resistant substitutions	~30 minutes
Tesamorelin	Trans-3-hexenoyl N-terminal modification	~30-40 minutes

Research Applications

Tesamorelin is used in studies examining:

Visceral adipose tissue (VAT) and body-composition endpoints
IGF-1 elevation and dose-response under a stabilized GHRH analog
Hepatic steatosis and liver-fat endpoints (documented in published HIV-lipodystrophy follow-on work)
Paired GHRH + GHRP study designs (commonly with Ipamorelin)
Comparative pharmacokinetics vs. Sermorelin and CJC-1295 No DAC
Long-duration GH/IGF-1 axis characterization

Specifications


Format	Lyophilized powder
Purity	≥99%
Aliases	Egrifta (trade name), TH9507, trans-3-hexenoyl GHRH (1-44)
Available sizes	5mg · 10mg
Storage	2-8°C unopened; stable 12+ months
Use	Research purposes only - not for human use

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Reconstitution parameters, solvent compatibility, and post-reconstitution stability for Tesamorelin are documented in the published peer-reviewed literature and standard peptide-chemistry references.

Reference Literature

Published clinical and preclinical Tesamorelin literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.

Common Questions About Tesamorelin Research

What does Tesamorelin do in research?

It activates the pituitary GHRH receptor and triggers a sustained pulse of GH release. Downstream, GH converts to IGF-1 in the liver, which is the primary biomarker tracked in most studies. Because Tesamorelin resists DPP-4 cleavage, the published literature includes visceral-fat and body-composition endpoints that shorter-acting GHRH analogs do not.

How does Tesamorelin compare to Sermorelin?

They are both GHRH analogs that hit the same pituitary receptor, but Tesamorelin is stabilized and Sermorelin is not. Sermorelin is the unmodified GHRH (1-29) fragment, degraded by DPP-4 within minutes. Tesamorelin is GHRH (1-44) with a trans-3-hexenoyl N-terminal modification that blocks DPP-4 cleavage and produces a longer, larger GH pulse.

How does Tesamorelin compare to Ipamorelin?

They act through different receptors. Tesamorelin is a GHRH analog (initiates the GH pulse via the GHRH receptor). Ipamorelin is a GHRP (amplifies the pulse via the ghrelin receptor). They are not interchangeable - researchers often pair them because the two pathways work together.

Is Tesamorelin FDA approved?

Yes. Tesamorelin is FDA-approved as Egrifta for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. It is not approved for any other indication. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.

How is Tesamorelin stored?

Unopened vials are stored at 2-8°C and stay stable for 12+ months. Once reconstituted with bacteriostatic water, the solution is kept at 2-8°C and used within 28-30 days.

Purity Guarantee

Every batch is ≥99% purity. Send us a COA from any independent test and we’ll issue store credit regardless of what it shows.